RSS-Feed abonnieren
DOI: 10.1055/s-0039-3403290
Association between weight loss and decline in FVC in patients with IPF*
Publikationsverlauf
Publikationsdatum:
28. Februar 2020 (online)
Introduction: Weight loss has been associated with worse survival in patients with idiopathic pulmonary fibrosis (IPF).
Aim: To assess the association between weight loss and disease progression measured as decline in forced vital capacity (FVC) in patients with IPF in the INPULSIS trials.
Methods: In post-hoc analyses, we assessed the rate of decline in FVC (mL/yr) over 52 weeks in subgroups by weight loss from baseline over 52 weeks (weight gain/no weight loss; 0 to ≤ 5% weight loss; > 5 to ≤ 10% weight loss; > 10% weight loss) using random coefficient regression.
Results: Among 421 patients in the placebo group, the proportions with no, 0 to ≤ 5%, > 5 to ≤ 10% and > 10% weight loss over 52 weeks were 45.6%, 34.7%, 13.1% and 6.7%, respectively. At baseline, subgroups with greater weight loss over 52 weeks had a higher mean age, lower proportion of males, lower mean DLco % predicted and lower mean FVC % predicted. In the placebo group, the mean rate of decline in FVC over 52 weeks increased with increasing weight loss ([Fig. 1]). In contrast, similar rates of decline in FVC were observed in nintedanib-treated patients (n = 635) irrespective of weight loss.
Conclusion: In the INPULSIS trials, patients with greater weight loss showed faster disease progression when treated with placebo, and a more pronounced treatment effect of nintedanib.
* presented at ERS 2019, ‡ presenting on behalf of the authors
#